A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

第3相実施中（募集終了） NCT05528510

対象疾患	Colitis, Ulcerative
相	第3相
スポンサー	Janssen Research & Development, LLC
ステータス	実施中（募集終了）
参加者数	418 名
介入（薬剤）	Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
開始日	2022年9月13日
完了日	2024年4月2日
結果公開日	2025年12月9日

概要

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).

Percentage of Participants in Clinical Remission at Week 12

Week 12 · Percentage of participants

Placebo	6.5 Percentage of participants
Combined Guselkumab 400 mg	27.6 Percentage of participants

p-value	<0.001
Adjusted Treatment Difference	21.1 (95% CI 14.5–27.6)

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
GI Permeability Change in Response to Aquamin® — James Varani
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University
ENhanced Recovery in CHildren Undergoing Surgery — Northwestern University

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。

English 한국어 日本語中文 Русский